12.73
2.33%
+0.29
Phibro Animal Health Corp. stock is currently priced at $12.73, with a 24-hour trading volume of 75,361.
It has seen a +2.33% increased in the last 24 hours and a -0.86% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $12.45 pivot point. If it approaches the $12.78 resistance level, significant changes may occur.
Previous Close:
$12.44
Open:
$12.41
24h Volume:
75,361
Market Cap:
$515.61M
Revenue:
$982.01M
Net Income/Loss:
$14.80M
P/E Ratio:
15.52
EPS:
0.82
Net Cash Flow:
$37.02M
1W Performance:
-4.29%
1M Performance:
-0.86%
6M Performance:
+17.11%
1Y Performance:
-17.07%
Phibro Animal Health Corp. Stock (PAHC) Company Profile
Name
Phibro Animal Health Corp.
Sector
Phone
201-329-7300
Address
Glenpointe Centre East, 3rd Floor Suite 21 300 Frank West Burr Boulevard, Teaneck, NJ
Phibro Animal Health Corp. Stock (PAHC) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-21-22 | Initiated | ROTH Capital | Buy |
Jul-25-22 | Downgrade | Barclays | Equal Weight → Underweight |
Jan-10-22 | Upgrade | Barclays | Underweight → Equal Weight |
Nov-18-21 | Initiated | Morgan Stanley | Equal-Weight |
Aug-05-21 | Resumed | Credit Suisse | Neutral |
Jul-07-21 | Downgrade | Barclays | Equal Weight → Underweight |
Aug-06-20 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
Feb-06-20 | Downgrade | Gabelli & Co | Buy → Hold |
Jan-28-20 | Upgrade | Barclays | Underweight → Equal Weight |
Sep-05-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
Aug-29-19 | Reiterated | BofA/Merrill | Underperform |
Jun-11-19 | Initiated | Barclays | Underweight |
May-23-19 | Initiated | Guggenheim | Neutral |
May-09-19 | Upgrade | Gabelli & Co | Hold → Buy |
Aug-23-17 | Resumed | BofA/Merrill | Underperform |
Jun-02-17 | Downgrade | Credit Suisse | Outperform → Neutral |
Dec-15-16 | Initiated | Piper Jaffray | Overweight |
Nov-11-16 | Downgrade | Macquarie | Neutral → Underperform |
Nov-10-16 | Downgrade | Gabelli & Co | Buy → Hold |
Apr-11-16 | Reiterated | Guggenheim | Buy |
Feb-04-16 | Initiated | Credit Suisse | Outperform |
Jan-15-16 | Downgrade | Barclays | Overweight → Underweight |
Sep-30-15 | Initiated | Gabelli & Co | Buy |
Apr-24-15 | Reiterated | Barclays | Overweight |
Apr-21-15 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
May-06-14 | Initiated | Barclays | Overweight |
View All
Phibro Animal Health Corp. Stock (PAHC) Latest News
Should Value Investors Buy Phibro Animal Health (PAHC) Stock?
Zacks Investment Research
Abbott (ABT) Tops Q1 Earnings and Revenue Estimates
Zacks Investment Research
Are Investors Undervaluing Phibro Animal Health (PAHC) Right Now?
Zacks Investment Research
Phibro Stock (PAHC) Rises 7% YTD: Will the Run Continue?
Zacks Investment Research
Here's Why Investors Should Buy Phibro (PAHC) Stock Now
Zacks Investment Research
Is Phibro Animal Health (PAHC) Stock Undervalued Right Now?
Zacks Investment Research
Phibro Animal Health Corp. Stock (PAHC) Financials Data
Phibro Animal Health Corp. (PAHC) Revenue 2024
PAHC reported a revenue (TTM) of $982.01 million for the quarter ending December 31, 2023, a +1.02% rise year-over-year.
Phibro Animal Health Corp. (PAHC) Net Income 2024
PAHC net income (TTM) was $14.80 million for the quarter ending December 31, 2023, a -59.17% decrease year-over-year.
Phibro Animal Health Corp. (PAHC) Cash Flow 2024
PAHC recorded a free cash flow (TTM) of $37.02 million for the quarter ending December 31, 2023, a +161.31% increase year-over-year.
Phibro Animal Health Corp. (PAHC) Earnings per Share 2024
PAHC earnings per share (TTM) was $0.37 for the quarter ending December 31, 2023, a -58.89% decline year-over-year.
About Phibro Animal Health Corp.
Phibro Animal Health Corporation operates as a diversified animal health and mineral nutrition company primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its animal health products also comprise antibacterials that are biological or chemical products used in the animal health industry to treat or to prevent diseases; anticoccidials primarily used to prevent and control the disease coccidiosis in poultry and cattle; anthelmintics to treat infestations of parasitic intestinal worms; and anti-bloat treatment products for cattle to control bloat in animals grazing on legume or wheat-pasture. In addition, the company offers nutritional specialty products, which enhance nutrition to help improve health and performance; and vaccines to prevent diseases primarily for the poultry and swine markets. Further, it manufactures and markets formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds; and various specialty ingredients for use in the personal care, industrial chemical, and chemical catalyst industries. The company sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle integrators, as well as through commercial animal feed manufacturers, wholesalers, and distributors. It also operates in Israel, Latin America, Canada, Europe, Africa, and the Asia/Pacific. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. The company is headquartered in Teaneck, New Jersey. Phibro Animal Health Corporation is a subsidiary of BFI Co., LLC.
Cap:
|
Volume (24h):